| 1 | first-line | 7,248 |
| 2 | second-line | 1,846 |
| 3 | third-line | 184 |
| 4 | first-choice | 181 |
| 5 | front-line | 180 |
| 6 | frontline | 171 |
| 7 | pi-based | 77 |
| 8 | first-step | 67 |
| 9 | post-remission | 62 |
| 10 | nnrti-based | 61 |
| 11 | postremission | 52 |
| 12 | response-guided | 45 |
| 13 | diuretic-based | 37 |
| 14 | substitutive | 33 |
| 15 | nevirapine-based | 32 |
| 16 | heat-moisture | 30 |
| 17 | heroin-assisted | 29 |
| 18 | second-step | 28 |
| 19 | firstline | 27 |
| 20 | pi-containing | 27 |
| 21 | nvp-based | 25 |
| 22 | compression-only | 24 |
| 23 | losartan-based | 22 |
| 24 | lpv/r-based | 20 |
| 25 | acdr | 18 |
| 26 | 1st-line | 17 |
| 27 | efv-based | 16 |
| 28 | lopinavir/ritonavir-based | 15 |
| 29 | monotherapeutic | 15 |
| 30 | nonplatinum | 15 |
| 31 | prethrombolytic | 15 |
| 32 | state-of-the | 15 |
| 33 | biomarker-directed | 14 |
| 34 | field-directed | 14 |
| 35 | methotrexate-based | 14 |
| 36 | last-resort | 13 |
| 37 | veno-arterial | 12 |
| 38 | non-systemic | 11 |
| 39 | over-the-head | 11 |
| 40 | post-docetaxel | 11 |
| 41 | acd/itd | 10 |
| 42 | coadjuvant | 10 |
| 43 | beta-blocker-based | 9 |
| 44 | fourth-line | 9 |
| 45 | individualising | 9 |
| 46 | metaphylactic | 9 |
| 47 | subsequent-line | 9 |
| 48 | thiazide-based | 9 |
| 49 | ccb-based | 8 |
| 50 | dispatcher-assisted | 8 |
| 51 | moist-heat | 8 |
| 52 | pre-referral | 8 |
| 53 | tdf-based | 8 |
| 54 | best-assessed | 7 |
| 55 | fluoroquinolone-based | 7 |
| 56 | hbv-active | 7 |
| 57 | heartcode | 7 |
| 58 | lopinavir-ritonavir-based | 7 |
| 59 | raltegravir-based | 7 |
| 60 | abacavir-based | 6 |
| 61 | abacavir-containing | 6 |
| 62 | atazanavir-based | 6 |
| 63 | basiliximab-based | 6 |
| 64 | bystander-initiated | 6 |
| 65 | cephalosporin-based | 6 |
| 66 | control/delayed | 6 |
| 67 | first-intention | 6 |
| 68 | prednisone-free | 6 |
| 69 | protease-inhibitor-based | 6 |
| 70 | su-per | 6 |
| 71 | anticonvulsivant | 5 |
| 72 | e-zes+3-month | 5 |
| 73 | guideline-adjusted | 5 |
| 74 | hands-only | 5 |
| 75 | last-line | 5 |
| 76 | lenalidomide-based | 5 |
| 77 | lymphodepleting | 5 |
| 78 | mudpack | 5 |
| 79 | multi-discipline | 5 |
| 80 | nvp-containing | 5 |
| 81 | olmesartan-based | 5 |
| 82 | student-assessed | 5 |
| 83 | tannase | 5 |
| 84 | cue-centered | 4 |
| 85 | d4t-based | 4 |
| 86 | diuretic-free | 4 |
| 87 | dsb-inducing | 4 |
| 88 | dual-nrti | 4 |
| 89 | fluvastatin-niacin | 4 |
| 90 | guideline-indicated | 4 |
| 91 | laver | 4 |
| 92 | minimal-guideline | 4 |
| 93 | pacemaker-based | 4 |
| 94 | planning-focused | 4 |
| 95 | remission-inducing | 4 |
| 96 | second/third-line | 4 |
| 97 | tenofovir-containing | 4 |
| 98 | three-combination | 4 |
| 99 | water/wastewater | 4 |
| 100 | acpuncture | 3 |
| 101 | adefovir-containing | 3 |
| 102 | amoxicillin-based | 3 |
| 103 | angiogenesis-targeted | 3 |
| 104 | azt-based | 3 |
| 105 | b-blocker-based | 3 |
| 106 | cetuximab-containing | 3 |
| 107 | coarse+lbg | 3 |
| 108 | cureative | 3 |
| 109 | d4t/3tc-based | 3 |
| 110 | doctor-monitored | 3 |
| 111 | efv-containing | 3 |
| 112 | fine+lbg | 3 |
| 113 | fist-line | 3 |
| 114 | hdl-atherosclerosis | 3 |
| 115 | hypoxia-modifying | 3 |
| 116 | lamivudine-based | 3 |
| 117 | lamivudine-containing | 3 |
| 118 | lopinavir/r-based | 3 |
| 119 | lvr-coil | 3 |
| 120 | molecular-targeting | 3 |
| 121 | nurse-monitored | 3 |
| 122 | oocyte-donation | 3 |
| 123 | pi-sparing | 3 |
| 124 | polychemotherapeutic | 3 |
| 125 | programme-assessed | 3 |
| 126 | single-controller | 3 |
| 127 | single-focused | 3 |
| 128 | suicide.standard | 3 |
| 129 | third-step | 3 |
| 130 | tpv/r-based | 3 |
| 131 | treatment/no | 3 |
| 132 | zdv/3tc-containing | 3 |
| 133 | +nl | 2 |
| 134 | 2-class | 2 |
| 135 | 47-j/cm | 2 |
| 136 | active-specific | 2 |
| 137 | acute-attack | 2 |
| 138 | adjuntive | 2 |
| 139 | anthracycline-and/or | 2 |
| 140 | antiamebic | 2 |
| 141 | antibio-tic | 2 |
| 142 | antisymptomatic | 2 |
| 143 | antitrichomonial | 2 |
| 144 | apheretic | 2 |
| 145 | ciclosporin-based | 2 |
| 146 | coequal | 2 |
| 147 | cyclopentyl-triazolo-pyrimidine | 2 |
| 148 | day-hospital-based | 2 |
| 149 | device-driven | 2 |
| 150 | diethylcarbamazine-albendazole | 2 |
| 151 | dispatch-assisted | 2 |
| 152 | domperidone-based | 2 |
| 153 | effect-free | 2 |
| 154 | ems-administered | 2 |
| 155 | fasting/preprandial | 2 |
| 156 | first/second-line | 2 |
| 157 | fludarabine-containing | 2 |
| 158 | genotype-directed | 2 |
| 159 | heme-independent | 2 |
| 160 | heparin-derived | 2 |
| 161 | intracanalicular | 2 |
| 162 | ivermectin-albendazole | 2 |
| 163 | life-prolonging/curative | 2 |
| 164 | lipostatic | 2 |
| 165 | longer-course | 2 |
| 166 | lt4-suppressive | 2 |
| 167 | neoadjvuant | 2 |
| 168 | never/past | 2 |
| 169 | next-line | 2 |
| 170 | non-mph | 2 |
| 171 | nonanthracycline-based | 2 |
| 172 | noncontinuous | 2 |
| 173 | omeprazole-amoxicillin | 2 |
| 174 | peg-interferon-α2/ribavirin | 2 |
| 175 | pertuzumab-based | 2 |
| 176 | phamacological | 2 |
| 177 | pi-free | 2 |
| 178 | pre-egfr | 2 |
| 179 | pre-operative/neo-adjuvant | 2 |
| 180 | pre-statin | 2 |
| 181 | premelting | 2 |
| 182 | psychiatric-psychodynamic | 2 |
| 183 | renoprotective-based | 2 |
| 184 | rhogdi2-induced | 2 |
| 185 | scapular-focused | 2 |
| 186 | specialist-delivered | 2 |
| 187 | standard-term | 2 |
| 188 | sulfur-based | 2 |
| 189 | switch-induction | 2 |
| 190 | t2-exchange | 2 |
| 191 | tace-alone | 2 |
| 192 | ternary-drug | 2 |
| 193 | tnf-alpha-antagonist | 2 |
| 194 | tubulin-inhibiting | 2 |
| 195 | tutor-less | 2 |
| 196 | veno-veno-arterial | 2 |
| 197 | zidovudine/ | 2 |
| 198 | zometa-femara | 2 |
| 199 | -demand | 1 |
| 200 | -nl+sb | 1 |
| 201 | -nl-sb | 1 |
| 202 | 0-12-month | 1 |
| 203 | 1-kgy | 1 |
| 204 | 1-methyl-1,2,3,6-tetrahydropiridine | 1 |
| 205 | 1-methyl-4-phenylpyridinium/mptp | 1 |
| 206 | 1-thyroxine | 1 |
| 207 | 2-regimen | 1 |
| 208 | 200-mg/day | 1 |
| 209 | 20‑week | 1 |
| 210 | 24th-hour | 1 |
| 211 | 3-nuc | 1 |
| 212 | 396,303 | 1 |
| 213 | 4-cycle | 1 |
| 214 | 400-mg/day | 1 |
| 215 | 4‑day | 1 |
| 216 | `current | 1 |
| 217 | above-examined | 1 |
| 218 | acetaminophen-only | 1 |
| 219 | acupucture | 1 |
| 220 | adrenal-corticosteroid | 1 |
| 221 | age-one | 1 |
| 222 | aix-les-bains | 1 |
| 223 | amfetamine-derived | 1 |
| 224 | aminolytic | 1 |
| 225 | andwell-tolerated | 1 |
| 226 | ang1-tie2 | 1 |
| 227 | anitiplatelet | 1 |
| 228 | anti-clot | 1 |
| 229 | anti-fading | 1 |
| 230 | anti-haemorrhoidal | 1 |
| 231 | anti-humoral | 1 |
| 232 | anti-lipemic | 1 |
| 233 | anti-misfolded | 1 |
| 234 | anti-vegfr3 | 1 |
| 235 | antiangina | 1 |
| 236 | anticholinergic-based | 1 |
| 237 | antigout | 1 |
| 238 | antiuberculosis | 1 |
| 239 | asthma.new | 1 |
| 240 | attempting/performing | 1 |
| 241 | atv/r-containing | 1 |
| 242 | autovac | 1 |
| 243 | awt/epat | 1 |
| 244 | b_cg | 1 |
| 245 | beds/kinetic | 1 |
| 246 | behavioral-weight-loss | 1 |
| 247 | benefit/additional | 1 |
| 248 | bpa-f-mediated | 1 |
| 249 | bsus-assisted | 1 |
| 250 | butylphthalide | 1 |
| 251 | c-met/alk | 1 |
| 252 | calgon | 1 |
| 253 | capsaicin-asa | 1 |
| 254 | cardiopreventive | 1 |
| 255 | cast-only | 1 |
| 256 | causitive | 1 |
| 257 | cbl-ipi | 1 |
| 258 | cbt/combined | 1 |
| 259 | cefuroxime-metronidazole | 1 |
| 260 | chc/placebo | 1 |
| 261 | cholinergic-based | 1 |
| 262 | chop/chop-like | 1 |
| 263 | cidr/dietary | 1 |
| 264 | cisplatin-taxol | 1 |
| 265 | cognitive-behaviorally-oriented | 1 |
| 266 | compliance-type-specific | 1 |
| 267 | conbined | 1 |
| 268 | consolidation/reintensification | 1 |
| 269 | contemporay | 1 |
| 270 | conventional-intensity | 1 |
| 271 | cost-relevant | 1 |
| 272 | cox-2-targeted | 1 |
| 273 | cremophor-solubilized | 1 |
| 274 | crf/lbn-mediated | 1 |
| 275 | crossover-corrected | 1 |
| 276 | d4t/3tc-containing | 1 |
| 277 | depilating | 1 |
| 278 | depression-moderated | 1 |
| 279 | diet-plus-active | 1 |
| 280 | disease-controlling | 1 |
| 281 | disease-free-interval | 1 |
| 282 | dormancy-breaking | 1 |
| 283 | drawback/shift | 1 |
| 284 | drug/insulin | 1 |
| 285 | eaaci/ga²len/edf/wao | 1 |
| 286 | empirical-evidence-based | 1 |
| 287 | emprical | 1 |
| 288 | endo-aural | 1 |
| 289 | erythromycin.pharmacological | 1 |
| 290 | europe.treatment | 1 |
| 291 | excisional/ablative | 1 |
| 292 | f-week | 1 |
| 293 | farmacologic | 1 |
| 294 | fdm-guided | 1 |
| 295 | feedback-monitored | 1 |
| 296 | fluorouracil-platinum | 1 |
| 297 | for/or | 1 |
| 298 | fully-active | 1 |
| 299 | galvanise | 1 |
| 300 | gas-generating | 1 |
| 301 | gemcitabine-bevacizumab | 1 |
| 302 | germanyfor | 1 |
| 303 | glucuronidase/sulfatase | 1 |
| 304 | grazing-only | 1 |
| 305 | group.any | 1 |
| 306 | group.hard | 1 |
| 307 | groups-three | 1 |
| 308 | haptotherapeutical | 1 |
| 309 | hdmtx-based | 1 |
| 310 | heamodialysis | 1 |
| 311 | heparin-mixed | 1 |
| 312 | hfdsc | 1 |
| 313 | hitorical | 1 |
| 314 | hylan-based | 1 |
| 315 | iakentro | 1 |
| 316 | igcnu-definitive | 1 |
| 317 | imatinib/nilotinib | 1 |
| 318 | imunosuppressive | 1 |
| 319 | inappropriate/ineffective | 1 |
| 320 | induction/adjuvant | 1 |
| 321 | intrventional | 1 |
| 322 | iodinating | 1 |
| 323 | ipolipidic | 1 |
| 324 | k≥2 | 1 |
| 325 | laboratory-spiked | 1 |
| 326 | larval-derived | 1 |
| 327 | laxative-based | 1 |
| 328 | lipid-friendly | 1 |
| 329 | longer-established | 1 |
| 330 | lpvr-based | 1 |
| 331 | lymphadenectomy-based | 1 |
| 332 | mainline | 1 |
| 333 | manually-derived | 1 |
| 334 | marijuana-dependence | 1 |
| 335 | marrow-versus-steroids | 1 |
| 336 | maximum-size | 1 |
| 337 | medicial | 1 |
| 338 | metoclopramide/phenothiazine | 1 |
| 339 | moxibustion-acupoint | 1 |
| 340 | mta-multimodal | 1 |
| 341 | naltrexone-based | 1 |
| 342 | negotiates | 1 |
| 343 | neoadjuvant/perioperative | 1 |
| 344 | neurostimulative | 1 |
| 345 | never/previous | 1 |
| 346 | niaspan-statin | 1 |
| 347 | nitrazepam-ethanol | 1 |
| 348 | non-formoterol | 1 |
| 349 | non-glycaemic | 1 |
| 350 | non-hps | 1 |
| 351 | non-mental-health | 1 |
| 352 | non-parasitological | 1 |
| 353 | non-pi-based | 1 |
| 354 | non-polymer-based | 1 |
| 355 | non-tnrti-based | 1 |
| 356 | nonagonist | 1 |
| 357 | nonmindfulness-based | 1 |
| 358 | nt-probnp-assisted | 1 |
| 359 | nurse-proctocol | 1 |
| 360 | nvp-tdf/ftc | 1 |
| 361 | observation-unit | 1 |
| 362 | oestrogen-alone | 1 |
| 363 | on-randomized | 1 |
| 364 | one‑year | 1 |
| 365 | opioid-replacement | 1 |
| 366 | out‑patient | 1 |
| 367 | pars-defined | 1 |
| 368 | pas-c-diet | 1 |
| 369 | pegylated-interferon-ribavirin | 1 |
| 370 | pentoxyfilline | 1 |
| 371 | peri-cycle | 1 |
| 372 | periodontological | 1 |
| 373 | perisurgical | 1 |
| 374 | personalizable | 1 |
| 375 | petacc3 | 1 |
| 376 | phenotype-guided | 1 |
| 377 | phlebosclerosing | 1 |
| 378 | phytosterol-enriched-chocolate | 1 |
| 379 | pi+2nrtis | 1 |
| 380 | pi-boosted | 1 |
| 381 | pilocarpine-stimulated | 1 |
| 382 | pioglitaone | 1 |
| 383 | pitavastain | 1 |
| 384 | pituitary-directed | 1 |
| 385 | placebo/no-drug | 1 |
| 386 | plasmapheretic | 1 |
| 387 | platin-pemetrexed | 1 |
| 388 | plurimodal | 1 |
| 389 | post-ac | 1 |
| 390 | postshortage | 1 |
| 391 | pr-based | 1 |
| 392 | pre-fluid | 1 |
| 393 | pre-gtx | 1 |
| 394 | pre-local | 1 |
| 395 | pre-telbivudine | 1 |
| 396 | prescription/nonprescription | 1 |
| 397 | pseudooctahedral | 1 |
| 398 | psl-antagonizing | 1 |
| 399 | psychoanalytic-orientated | 1 |
| 400 | psychological/psychiatric | 1 |
| 401 | psychostimulant-dependence | 1 |
| 402 | psychotherapy-only | 1 |
| 403 | pth/ibandronate | 1 |
| 404 | rapamune-based | 1 |
| 405 | re-prescribed | 1 |
| 406 | real-patients | 1 |
| 407 | remission-inductive | 1 |
| 408 | repriming | 1 |
| 409 | revascularizational | 1 |
| 410 | review.early | 1 |
| 411 | rhgh=t | 1 |
| 412 | riociguat/placebo | 1 |
| 413 | roentrgenosurgical | 1 |
| 414 | routine/first-line | 1 |
| 415 | sasb-coded | 1 |
| 416 | screeningrelated | 1 |
| 417 | second/salvage | 1 |
| 418 | separately-administered | 1 |
| 419 | sex-tailored | 1 |
| 420 | sga-chronic | 1 |
| 421 | specol | 1 |
| 422 | sris/clomipramine | 1 |
| 423 | srp+prodentis | 1 |
| 424 | sso-involved | 1 |
| 425 | streptokinase/control | 1 |
| 426 | strips-only | 1 |
| 427 | structure-forming | 1 |
| 428 | subgroup-level | 1 |
| 429 | sud/ptsd | 1 |
| 430 | tam/mpa | 1 |
| 431 | tangent-only | 1 |
| 432 | tetra-drug | 1 |
| 433 | the:1. | 1 |
| 434 | thefirst-line | 1 |
| 435 | thermal-acid | 1 |
| 436 | thiazolidiendione | 1 |
| 437 | tmd-relared | 1 |
| 438 | tnrti-sparing | 1 |
| 439 | treatment+only | 1 |
| 440 | two-professional-rescuer | 1 |
| 441 | un-allocated | 1 |
| 442 | vacuum-drying | 1 |
| 443 | virologically-active | 1 |
| 444 | vlcd-based | 1 |
| 445 | voriconazole-alone | 1 |
| 446 | wellness/ | 1 |
| 447 | within-clinic | 1 |
| 448 | zdv-based | 1 |
| 449 | zdv/ddi-based | 1 |
| 450 | zometa/femara | 1 |
| 451 | ≥12-week | 1 |
| 452 | ≥2nd-salvage | 1 |
| 1 | +nl | 2 |
| 2 | -demand | 1 |
| 3 | -nl+sb | 1 |
| 4 | -nl-sb | 1 |
| 5 | 0-12-month | 1 |
| 6 | 1-kgy | 1 |
| 7 | 1-methyl-1,2,3,6-tetrahydropiridine | 1 |
| 8 | 1-methyl-4-phenylpyridinium/mptp | 1 |
| 9 | 1-thyroxine | 1 |
| 10 | 1st-line | 17 |
| 11 | 2-class | 2 |
| 12 | 2-regimen | 1 |
| 13 | 200-mg/day | 1 |
| 14 | 20‑week | 1 |
| 15 | 24th-hour | 1 |
| 16 | 3-nuc | 1 |
| 17 | 396,303 | 1 |
| 18 | 4-cycle | 1 |
| 19 | 400-mg/day | 1 |
| 20 | 47-j/cm | 2 |
| 21 | 4‑day | 1 |
| 22 | `current | 1 |
| 23 | abacavir-based | 6 |
| 24 | abacavir-containing | 6 |
| 25 | above-examined | 1 |
| 26 | acd/itd | 10 |
| 27 | acdr | 18 |
| 28 | acetaminophen-only | 1 |
| 29 | acpuncture | 3 |
| 30 | active-specific | 2 |
| 31 | acupucture | 1 |
| 32 | acute-attack | 2 |
| 33 | adefovir-containing | 3 |
| 34 | adjuntive | 2 |
| 35 | adrenal-corticosteroid | 1 |
| 36 | age-one | 1 |
| 37 | aix-les-bains | 1 |
| 38 | amfetamine-derived | 1 |
| 39 | aminolytic | 1 |
| 40 | amoxicillin-based | 3 |
| 41 | andwell-tolerated | 1 |
| 42 | ang1-tie2 | 1 |
| 43 | angiogenesis-targeted | 3 |
| 44 | anitiplatelet | 1 |
| 45 | anthracycline-and/or | 2 |
| 46 | anti-clot | 1 |
| 47 | anti-fading | 1 |
| 48 | anti-haemorrhoidal | 1 |
| 49 | anti-humoral | 1 |
| 50 | anti-lipemic | 1 |
| 51 | anti-misfolded | 1 |
| 52 | anti-vegfr3 | 1 |
| 53 | antiamebic | 2 |
| 54 | antiangina | 1 |
| 55 | antibio-tic | 2 |
| 56 | anticholinergic-based | 1 |
| 57 | anticonvulsivant | 5 |
| 58 | antigout | 1 |
| 59 | antisymptomatic | 2 |
| 60 | antitrichomonial | 2 |
| 61 | antiuberculosis | 1 |
| 62 | apheretic | 2 |
| 63 | asthma.new | 1 |
| 64 | atazanavir-based | 6 |
| 65 | attempting/performing | 1 |
| 66 | atv/r-containing | 1 |
| 67 | autovac | 1 |
| 68 | awt/epat | 1 |
| 69 | azt-based | 3 |
| 70 | b-blocker-based | 3 |
| 71 | b_cg | 1 |
| 72 | basiliximab-based | 6 |
| 73 | beds/kinetic | 1 |
| 74 | behavioral-weight-loss | 1 |
| 75 | benefit/additional | 1 |
| 76 | best-assessed | 7 |
| 77 | beta-blocker-based | 9 |
| 78 | biomarker-directed | 14 |
| 79 | bpa-f-mediated | 1 |
| 80 | bsus-assisted | 1 |
| 81 | butylphthalide | 1 |
| 82 | bystander-initiated | 6 |
| 83 | c-met/alk | 1 |
| 84 | calgon | 1 |
| 85 | capsaicin-asa | 1 |
| 86 | cardiopreventive | 1 |
| 87 | cast-only | 1 |
| 88 | causitive | 1 |
| 89 | cbl-ipi | 1 |
| 90 | cbt/combined | 1 |
| 91 | ccb-based | 8 |
| 92 | cefuroxime-metronidazole | 1 |
| 93 | cephalosporin-based | 6 |
| 94 | cetuximab-containing | 3 |
| 95 | chc/placebo | 1 |
| 96 | cholinergic-based | 1 |
| 97 | chop/chop-like | 1 |
| 98 | ciclosporin-based | 2 |
| 99 | cidr/dietary | 1 |
| 100 | cisplatin-taxol | 1 |
| 101 | coadjuvant | 10 |
| 102 | coarse+lbg | 3 |
| 103 | coequal | 2 |
| 104 | cognitive-behaviorally-oriented | 1 |
| 105 | compliance-type-specific | 1 |
| 106 | compression-only | 24 |
| 107 | conbined | 1 |
| 108 | consolidation/reintensification | 1 |
| 109 | contemporay | 1 |
| 110 | control/delayed | 6 |
| 111 | conventional-intensity | 1 |
| 112 | cost-relevant | 1 |
| 113 | cox-2-targeted | 1 |
| 114 | cremophor-solubilized | 1 |
| 115 | crf/lbn-mediated | 1 |
| 116 | crossover-corrected | 1 |
| 117 | cue-centered | 4 |
| 118 | cureative | 3 |
| 119 | cyclopentyl-triazolo-pyrimidine | 2 |
| 120 | d4t-based | 4 |
| 121 | d4t/3tc-based | 3 |
| 122 | d4t/3tc-containing | 1 |
| 123 | day-hospital-based | 2 |
| 124 | depilating | 1 |
| 125 | depression-moderated | 1 |
| 126 | device-driven | 2 |
| 127 | diet-plus-active | 1 |
| 128 | diethylcarbamazine-albendazole | 2 |
| 129 | disease-controlling | 1 |
| 130 | disease-free-interval | 1 |
| 131 | dispatch-assisted | 2 |
| 132 | dispatcher-assisted | 8 |
| 133 | diuretic-based | 37 |
| 134 | diuretic-free | 4 |
| 135 | doctor-monitored | 3 |
| 136 | domperidone-based | 2 |
| 137 | dormancy-breaking | 1 |
| 138 | drawback/shift | 1 |
| 139 | drug/insulin | 1 |
| 140 | dsb-inducing | 4 |
| 141 | dual-nrti | 4 |
| 142 | e-zes+3-month | 5 |
| 143 | eaaci/ga²len/edf/wao | 1 |
| 144 | effect-free | 2 |
| 145 | efv-based | 16 |
| 146 | efv-containing | 3 |
| 147 | empirical-evidence-based | 1 |
| 148 | emprical | 1 |
| 149 | ems-administered | 2 |
| 150 | endo-aural | 1 |
| 151 | erythromycin.pharmacological | 1 |
| 152 | europe.treatment | 1 |
| 153 | excisional/ablative | 1 |
| 154 | f-week | 1 |
| 155 | farmacologic | 1 |
| 156 | fasting/preprandial | 2 |
| 157 | fdm-guided | 1 |
| 158 | feedback-monitored | 1 |
| 159 | field-directed | 14 |
| 160 | fine+lbg | 3 |
| 161 | first-choice | 181 |
| 162 | first-intention | 6 |
| 163 | first-line | 7,248 |
| 164 | first-step | 67 |
| 165 | first/second-line | 2 |
| 166 | firstline | 27 |
| 167 | fist-line | 3 |
| 168 | fludarabine-containing | 2 |
| 169 | fluoroquinolone-based | 7 |
| 170 | fluorouracil-platinum | 1 |
| 171 | fluvastatin-niacin | 4 |
| 172 | for/or | 1 |
| 173 | fourth-line | 9 |
| 174 | front-line | 180 |
| 175 | frontline | 171 |
| 176 | fully-active | 1 |
| 177 | galvanise | 1 |
| 178 | gas-generating | 1 |
| 179 | gemcitabine-bevacizumab | 1 |
| 180 | genotype-directed | 2 |
| 181 | germanyfor | 1 |
| 182 | glucuronidase/sulfatase | 1 |
| 183 | grazing-only | 1 |
| 184 | group.any | 1 |
| 185 | group.hard | 1 |
| 186 | groups-three | 1 |
| 187 | guideline-adjusted | 5 |
| 188 | guideline-indicated | 4 |
| 189 | hands-only | 5 |
| 190 | haptotherapeutical | 1 |
| 191 | hbv-active | 7 |
| 192 | hdl-atherosclerosis | 3 |
| 193 | hdmtx-based | 1 |
| 194 | heamodialysis | 1 |
| 195 | heartcode | 7 |
| 196 | heat-moisture | 30 |
| 197 | heme-independent | 2 |
| 198 | heparin-derived | 2 |
| 199 | heparin-mixed | 1 |
| 200 | heroin-assisted | 29 |
| 201 | hfdsc | 1 |
| 202 | hitorical | 1 |
| 203 | hylan-based | 1 |
| 204 | hypoxia-modifying | 3 |
| 205 | iakentro | 1 |
| 206 | igcnu-definitive | 1 |
| 207 | imatinib/nilotinib | 1 |
| 208 | imunosuppressive | 1 |
| 209 | inappropriate/ineffective | 1 |
| 210 | individualising | 9 |
| 211 | induction/adjuvant | 1 |
| 212 | intracanalicular | 2 |
| 213 | intrventional | 1 |
| 214 | iodinating | 1 |
| 215 | ipolipidic | 1 |
| 216 | ivermectin-albendazole | 2 |
| 217 | k≥2 | 1 |
| 218 | laboratory-spiked | 1 |
| 219 | lamivudine-based | 3 |
| 220 | lamivudine-containing | 3 |
| 221 | larval-derived | 1 |
| 222 | last-line | 5 |
| 223 | last-resort | 13 |
| 224 | laver | 4 |
| 225 | laxative-based | 1 |
| 226 | lenalidomide-based | 5 |
| 227 | life-prolonging/curative | 2 |
| 228 | lipid-friendly | 1 |
| 229 | lipostatic | 2 |
| 230 | longer-course | 2 |
| 231 | longer-established | 1 |
| 232 | lopinavir-ritonavir-based | 7 |
| 233 | lopinavir/r-based | 3 |
| 234 | lopinavir/ritonavir-based | 15 |
| 235 | losartan-based | 22 |
| 236 | lpv/r-based | 20 |
| 237 | lpvr-based | 1 |
| 238 | lt4-suppressive | 2 |
| 239 | lvr-coil | 3 |
| 240 | lymphadenectomy-based | 1 |
| 241 | lymphodepleting | 5 |
| 242 | mainline | 1 |
| 243 | manually-derived | 1 |
| 244 | marijuana-dependence | 1 |
| 245 | marrow-versus-steroids | 1 |
| 246 | maximum-size | 1 |
| 247 | medicial | 1 |
| 248 | metaphylactic | 9 |
| 249 | methotrexate-based | 14 |
| 250 | metoclopramide/phenothiazine | 1 |
| 251 | minimal-guideline | 4 |
| 252 | moist-heat | 8 |
| 253 | molecular-targeting | 3 |
| 254 | monotherapeutic | 15 |
| 255 | moxibustion-acupoint | 1 |
| 256 | mta-multimodal | 1 |
| 257 | mudpack | 5 |
| 258 | multi-discipline | 5 |
| 259 | naltrexone-based | 1 |
| 260 | negotiates | 1 |
| 261 | neoadjuvant/perioperative | 1 |
| 262 | neoadjvuant | 2 |
| 263 | neurostimulative | 1 |
| 264 | never/past | 2 |
| 265 | never/previous | 1 |
| 266 | nevirapine-based | 32 |
| 267 | next-line | 2 |
| 268 | niaspan-statin | 1 |
| 269 | nitrazepam-ethanol | 1 |
| 270 | nnrti-based | 61 |
| 271 | non-formoterol | 1 |
| 272 | non-glycaemic | 1 |
| 273 | non-hps | 1 |
| 274 | non-mental-health | 1 |
| 275 | non-mph | 2 |
| 276 | non-parasitological | 1 |
| 277 | non-pi-based | 1 |
| 278 | non-polymer-based | 1 |
| 279 | non-systemic | 11 |
| 280 | non-tnrti-based | 1 |
| 281 | nonagonist | 1 |
| 282 | nonanthracycline-based | 2 |
| 283 | noncontinuous | 2 |
| 284 | nonmindfulness-based | 1 |
| 285 | nonplatinum | 15 |
| 286 | nt-probnp-assisted | 1 |
| 287 | nurse-monitored | 3 |
| 288 | nurse-proctocol | 1 |
| 289 | nvp-based | 25 |
| 290 | nvp-containing | 5 |
| 291 | nvp-tdf/ftc | 1 |
| 292 | observation-unit | 1 |
| 293 | oestrogen-alone | 1 |
| 294 | olmesartan-based | 5 |
| 295 | omeprazole-amoxicillin | 2 |
| 296 | on-randomized | 1 |
| 297 | one‑year | 1 |
| 298 | oocyte-donation | 3 |
| 299 | opioid-replacement | 1 |
| 300 | out‑patient | 1 |
| 301 | over-the-head | 11 |
| 302 | pacemaker-based | 4 |
| 303 | pars-defined | 1 |
| 304 | pas-c-diet | 1 |
| 305 | peg-interferon-α2/ribavirin | 2 |
| 306 | pegylated-interferon-ribavirin | 1 |
| 307 | pentoxyfilline | 1 |
| 308 | peri-cycle | 1 |
| 309 | periodontological | 1 |
| 310 | perisurgical | 1 |
| 311 | personalizable | 1 |
| 312 | pertuzumab-based | 2 |
| 313 | petacc3 | 1 |
| 314 | phamacological | 2 |
| 315 | phenotype-guided | 1 |
| 316 | phlebosclerosing | 1 |
| 317 | phytosterol-enriched-chocolate | 1 |
| 318 | pi+2nrtis | 1 |
| 319 | pi-based | 77 |
| 320 | pi-boosted | 1 |
| 321 | pi-containing | 27 |
| 322 | pi-free | 2 |
| 323 | pi-sparing | 3 |
| 324 | pilocarpine-stimulated | 1 |
| 325 | pioglitaone | 1 |
| 326 | pitavastain | 1 |
| 327 | pituitary-directed | 1 |
| 328 | placebo/no-drug | 1 |
| 329 | planning-focused | 4 |
| 330 | plasmapheretic | 1 |
| 331 | platin-pemetrexed | 1 |
| 332 | plurimodal | 1 |
| 333 | polychemotherapeutic | 3 |
| 334 | post-ac | 1 |
| 335 | post-docetaxel | 11 |
| 336 | post-remission | 62 |
| 337 | postremission | 52 |
| 338 | postshortage | 1 |
| 339 | pr-based | 1 |
| 340 | pre-egfr | 2 |
| 341 | pre-fluid | 1 |
| 342 | pre-gtx | 1 |
| 343 | pre-local | 1 |
| 344 | pre-operative/neo-adjuvant | 2 |
| 345 | pre-referral | 8 |
| 346 | pre-statin | 2 |
| 347 | pre-telbivudine | 1 |
| 348 | prednisone-free | 6 |
| 349 | premelting | 2 |
| 350 | prescription/nonprescription | 1 |
| 351 | prethrombolytic | 15 |
| 352 | programme-assessed | 3 |
| 353 | protease-inhibitor-based | 6 |
| 354 | pseudooctahedral | 1 |
| 355 | psl-antagonizing | 1 |
| 356 | psychiatric-psychodynamic | 2 |
| 357 | psychoanalytic-orientated | 1 |
| 358 | psychological/psychiatric | 1 |
| 359 | psychostimulant-dependence | 1 |
| 360 | psychotherapy-only | 1 |
| 361 | pth/ibandronate | 1 |
| 362 | raltegravir-based | 7 |
| 363 | rapamune-based | 1 |
| 364 | re-prescribed | 1 |
| 365 | real-patients | 1 |
| 366 | remission-inducing | 4 |
| 367 | remission-inductive | 1 |
| 368 | renoprotective-based | 2 |
| 369 | repriming | 1 |
| 370 | response-guided | 45 |
| 371 | revascularizational | 1 |
| 372 | review.early | 1 |
| 373 | rhgh=t | 1 |
| 374 | rhogdi2-induced | 2 |
| 375 | riociguat/placebo | 1 |
| 376 | roentrgenosurgical | 1 |
| 377 | routine/first-line | 1 |
| 378 | sasb-coded | 1 |
| 379 | scapular-focused | 2 |
| 380 | screeningrelated | 1 |
| 381 | second-line | 1,846 |
| 382 | second-step | 28 |
| 383 | second/salvage | 1 |
| 384 | second/third-line | 4 |
| 385 | separately-administered | 1 |
| 386 | sex-tailored | 1 |
| 387 | sga-chronic | 1 |
| 388 | single-controller | 3 |
| 389 | single-focused | 3 |
| 390 | specialist-delivered | 2 |
| 391 | specol | 1 |
| 392 | sris/clomipramine | 1 |
| 393 | srp+prodentis | 1 |
| 394 | sso-involved | 1 |
| 395 | standard-term | 2 |
| 396 | state-of-the | 15 |
| 397 | streptokinase/control | 1 |
| 398 | strips-only | 1 |
| 399 | structure-forming | 1 |
| 400 | student-assessed | 5 |
| 401 | su-per | 6 |
| 402 | subgroup-level | 1 |
| 403 | subsequent-line | 9 |
| 404 | substitutive | 33 |
| 405 | sud/ptsd | 1 |
| 406 | suicide.standard | 3 |
| 407 | sulfur-based | 2 |
| 408 | switch-induction | 2 |
| 409 | t2-exchange | 2 |
| 410 | tace-alone | 2 |
| 411 | tam/mpa | 1 |
| 412 | tangent-only | 1 |
| 413 | tannase | 5 |
| 414 | tdf-based | 8 |
| 415 | tenofovir-containing | 4 |
| 416 | ternary-drug | 2 |
| 417 | tetra-drug | 1 |
| 418 | the:1. | 1 |
| 419 | thefirst-line | 1 |
| 420 | thermal-acid | 1 |
| 421 | thiazide-based | 9 |
| 422 | thiazolidiendione | 1 |
| 423 | third-line | 184 |
| 424 | third-step | 3 |
| 425 | three-combination | 4 |
| 426 | tmd-relared | 1 |
| 427 | tnf-alpha-antagonist | 2 |
| 428 | tnrti-sparing | 1 |
| 429 | tpv/r-based | 3 |
| 430 | treatment+only | 1 |
| 431 | treatment/no | 3 |
| 432 | tubulin-inhibiting | 2 |
| 433 | tutor-less | 2 |
| 434 | two-professional-rescuer | 1 |
| 435 | un-allocated | 1 |
| 436 | vacuum-drying | 1 |
| 437 | veno-arterial | 12 |
| 438 | veno-veno-arterial | 2 |
| 439 | virologically-active | 1 |
| 440 | vlcd-based | 1 |
| 441 | voriconazole-alone | 1 |
| 442 | water/wastewater | 4 |
| 443 | wellness/ | 1 |
| 444 | within-clinic | 1 |
| 445 | zdv-based | 1 |
| 446 | zdv/3tc-containing | 3 |
| 447 | zdv/ddi-based | 1 |
| 448 | zidovudine/ | 2 |
| 449 | zometa-femara | 2 |
| 450 | zometa/femara | 1 |
| 451 | ≥12-week | 1 |
| 452 | ≥2nd-salvage | 1 |
| 1 | the:1. | 1 |
| 2 | zidovudine/ | 2 |
| 3 | wellness/ | 1 |
| 4 | ang1-tie2 | 1 |
| 5 | k≥2 | 1 |
| 6 | 396,303 | 1 |
| 7 | petacc3 | 1 |
| 8 | anti-vegfr3 | 1 |
| 9 | antiangina | 1 |
| 10 | tam/mpa | 1 |
| 11 | zometa-femara | 2 |
| 12 | zometa/femara | 1 |
| 13 | capsaicin-asa | 1 |
| 14 | gemcitabine-bevacizumab | 1 |
| 15 | imatinib/nilotinib | 1 |
| 16 | -nl+sb | 1 |
| 17 | -nl-sb | 1 |
| 18 | post-ac | 1 |
| 19 | autovac | 1 |
| 20 | antiamebic | 2 |
| 21 | ipolipidic | 1 |
| 22 | compliance-type-specific | 1 |
| 23 | active-specific | 2 |
| 24 | farmacologic | 1 |
| 25 | psychiatric-psychodynamic | 2 |
| 26 | non-glycaemic | 1 |
| 27 | anti-lipemic | 1 |
| 28 | non-systemic | 11 |
| 29 | within-clinic | 1 |
| 30 | sga-chronic | 1 |
| 31 | psychological/psychiatric | 1 |
| 32 | antibio-tic | 2 |
| 33 | antisymptomatic | 2 |
| 34 | lipostatic | 2 |
| 35 | metaphylactic | 9 |
| 36 | beds/kinetic | 1 |
| 37 | apheretic | 2 |
| 38 | plasmapheretic | 1 |
| 39 | polychemotherapeutic | 3 |
| 40 | monotherapeutic | 15 |
| 41 | prethrombolytic | 15 |
| 42 | aminolytic | 1 |
| 43 | hfdsc | 1 |
| 44 | nvp-tdf/ftc | 1 |
| 45 | 3-nuc | 1 |
| 46 | over-the-head | 11 |
| 47 | re-prescribed | 1 |
| 48 | rhogdi2-induced | 2 |
| 49 | phenotype-guided | 1 |
| 50 | response-guided | 45 |
| 51 | fdm-guided | 1 |
| 52 | anti-misfolded | 1 |
| 53 | sasb-coded | 1 |
| 54 | longer-established | 1 |
| 55 | laboratory-spiked | 1 |
| 56 | cbt/combined | 1 |
| 57 | conbined | 1 |
| 58 | pars-defined | 1 |
| 59 | above-examined | 1 |
| 60 | tmd-relared | 1 |
| 61 | cue-centered | 4 |
| 62 | ems-administered | 2 |
| 63 | separately-administered | 1 |
| 64 | specialist-delivered | 2 |
| 65 | sex-tailored | 1 |
| 66 | nurse-monitored | 3 |
| 67 | feedback-monitored | 1 |
| 68 | doctor-monitored | 3 |
| 69 | basiliximab-based | 6 |
| 70 | pertuzumab-based | 2 |
| 71 | ccb-based | 8 |
| 72 | cholinergic-based | 1 |
| 73 | anticholinergic-based | 1 |
| 74 | diuretic-based | 37 |
| 75 | d4t/3tc-based | 3 |
| 76 | vlcd-based | 1 |
| 77 | empirical-evidence-based | 1 |
| 78 | lenalidomide-based | 5 |
| 79 | thiazide-based | 9 |
| 80 | lamivudine-based | 3 |
| 81 | nonanthracycline-based | 2 |
| 82 | nevirapine-based | 32 |
| 83 | domperidone-based | 2 |
| 84 | fluoroquinolone-based | 7 |
| 85 | naltrexone-based | 1 |
| 86 | rapamune-based | 1 |
| 87 | methotrexate-based | 14 |
| 88 | laxative-based | 1 |
| 89 | renoprotective-based | 2 |
| 90 | tdf-based | 8 |
| 91 | zdv/ddi-based | 1 |
| 92 | pi-based | 77 |
| 93 | non-pi-based | 1 |
| 94 | nnrti-based | 61 |
| 95 | non-tnrti-based | 1 |
| 96 | day-hospital-based | 2 |
| 97 | hylan-based | 1 |
| 98 | olmesartan-based | 5 |
| 99 | losartan-based | 22 |
| 100 | amoxicillin-based | 3 |
| 101 | cephalosporin-based | 6 |
| 102 | ciclosporin-based | 2 |
| 103 | nvp-based | 25 |
| 104 | lopinavir/r-based | 3 |
| 105 | lpv/r-based | 20 |
| 106 | tpv/r-based | 3 |
| 107 | pacemaker-based | 4 |
| 108 | beta-blocker-based | 9 |
| 109 | b-blocker-based | 3 |
| 110 | non-polymer-based | 1 |
| 111 | abacavir-based | 6 |
| 112 | atazanavir-based | 6 |
| 113 | lopinavir-ritonavir-based | 7 |
| 114 | lopinavir/ritonavir-based | 15 |
| 115 | raltegravir-based | 7 |
| 116 | protease-inhibitor-based | 6 |
| 117 | pr-based | 1 |
| 118 | sulfur-based | 2 |
| 119 | lpvr-based | 1 |
| 120 | nonmindfulness-based | 1 |
| 121 | d4t-based | 4 |
| 122 | azt-based | 3 |
| 123 | zdv-based | 1 |
| 124 | efv-based | 16 |
| 125 | hdmtx-based | 1 |
| 126 | lymphadenectomy-based | 1 |
| 127 | programme-assessed | 3 |
| 128 | student-assessed | 5 |
| 129 | best-assessed | 7 |
| 130 | single-focused | 3 |
| 131 | planning-focused | 4 |
| 132 | scapular-focused | 2 |
| 133 | guideline-indicated | 4 |
| 134 | un-allocated | 1 |
| 135 | bpa-f-mediated | 1 |
| 136 | crf/lbn-mediated | 1 |
| 137 | bystander-initiated | 6 |
| 138 | screeningrelated | 1 |
| 139 | pilocarpine-stimulated | 1 |
| 140 | depression-moderated | 1 |
| 141 | andwell-tolerated | 1 |
| 142 | psychoanalytic-orientated | 1 |
| 143 | field-directed | 14 |
| 144 | genotype-directed | 2 |
| 145 | biomarker-directed | 14 |
| 146 | pituitary-directed | 1 |
| 147 | crossover-corrected | 1 |
| 148 | cox-2-targeted | 1 |
| 149 | angiogenesis-targeted | 3 |
| 150 | cognitive-behaviorally-oriented | 1 |
| 151 | dispatch-assisted | 2 |
| 152 | heroin-assisted | 29 |
| 153 | nt-probnp-assisted | 1 |
| 154 | dispatcher-assisted | 8 |
| 155 | bsus-assisted | 1 |
| 156 | pi-boosted | 1 |
| 157 | guideline-adjusted | 5 |
| 158 | amfetamine-derived | 1 |
| 159 | larval-derived | 1 |
| 160 | heparin-derived | 2 |
| 161 | manually-derived | 1 |
| 162 | sso-involved | 1 |
| 163 | platin-pemetrexed | 1 |
| 164 | heparin-mixed | 1 |
| 165 | control/delayed | 6 |
| 166 | cremophor-solubilized | 1 |
| 167 | on-randomized | 1 |
| 168 | thermal-acid | 1 |
| 169 | adrenal-corticosteroid | 1 |
| 170 | pre-fluid | 1 |
| 171 | -demand | 1 |
| 172 | suicide.standard | 3 |
| 173 | group.hard | 1 |
| 174 | sud/ptsd | 1 |
| 175 | acd/itd | 10 |
| 176 | first-choice | 181 |
| 177 | marijuana-dependence | 1 |
| 178 | psychostimulant-dependence | 1 |
| 179 | butylphthalide | 1 |
| 180 | heartcode | 7 |
| 181 | diuretic-free | 4 |
| 182 | prednisone-free | 6 |
| 183 | pi-free | 2 |
| 184 | effect-free | 2 |
| 185 | groups-three | 1 |
| 186 | postshortage | 1 |
| 187 | ≥2nd-salvage | 1 |
| 188 | second/salvage | 1 |
| 189 | t2-exchange | 2 |
| 190 | state-of-the | 15 |
| 191 | chop/chop-like | 1 |
| 192 | personalizable | 1 |
| 193 | 4-cycle | 1 |
| 194 | peri-cycle | 1 |
| 195 | cefuroxime-metronidazole | 1 |
| 196 | diethylcarbamazine-albendazole | 2 |
| 197 | ivermectin-albendazole | 2 |
| 198 | cyclopentyl-triazolo-pyrimidine | 2 |
| 199 | 1-methyl-1,2,3,6-tetrahydropiridine | 1 |
| 200 | pre-telbivudine | 1 |
| 201 | second-line | 1,846 |
| 202 | first/second-line | 2 |
| 203 | third-line | 184 |
| 204 | second/third-line | 4 |
| 205 | fourth-line | 9 |
| 206 | subsequent-line | 9 |
| 207 | front-line | 180 |
| 208 | 1st-line | 17 |
| 209 | last-line | 5 |
| 210 | fist-line | 3 |
| 211 | first-line | 7,248 |
| 212 | routine/first-line | 1 |
| 213 | thefirst-line | 1 |
| 214 | next-line | 2 |
| 215 | minimal-guideline | 4 |
| 216 | pentoxyfilline | 1 |
| 217 | mainline | 1 |
| 218 | multi-discipline | 5 |
| 219 | frontline | 171 |
| 220 | firstline | 27 |
| 221 | sris/clomipramine | 1 |
| 222 | 1-thyroxine | 1 |
| 223 | metoclopramide/phenothiazine | 1 |
| 224 | age-one | 1 |
| 225 | pioglitaone | 1 |
| 226 | thiazolidiendione | 1 |
| 227 | tace-alone | 2 |
| 228 | voriconazole-alone | 1 |
| 229 | oestrogen-alone | 1 |
| 230 | acpuncture | 3 |
| 231 | acupucture | 1 |
| 232 | heat-moisture | 30 |
| 233 | tannase | 5 |
| 234 | glucuronidase/sulfatase | 1 |
| 235 | galvanise | 1 |
| 236 | longer-course | 2 |
| 237 | phytosterol-enriched-chocolate | 1 |
| 238 | pth/ibandronate | 1 |
| 239 | lt4-suppressive | 2 |
| 240 | imunosuppressive | 1 |
| 241 | cureative | 3 |
| 242 | excisional/ablative | 1 |
| 243 | neurostimulative | 1 |
| 244 | neoadjuvant/perioperative | 1 |
| 245 | life-prolonging/curative | 2 |
| 246 | diet-plus-active | 1 |
| 247 | hbv-active | 7 |
| 248 | virologically-active | 1 |
| 249 | fully-active | 1 |
| 250 | inappropriate/ineffective | 1 |
| 251 | remission-inductive | 1 |
| 252 | igcnu-definitive | 1 |
| 253 | causitive | 1 |
| 254 | cardiopreventive | 1 |
| 255 | adjuntive | 2 |
| 256 | substitutive | 33 |
| 257 | maximum-size | 1 |
| 258 | fine+lbg | 3 |
| 259 | coarse+lbg | 3 |
| 260 | b_cg | 1 |
| 261 | dsb-inducing | 4 |
| 262 | remission-inducing | 4 |
| 263 | anti-fading | 1 |
| 264 | dormancy-breaking | 1 |
| 265 | disease-controlling | 1 |
| 266 | repriming | 1 |
| 267 | structure-forming | 1 |
| 268 | attempting/performing | 1 |
| 269 | cetuximab-containing | 3 |
| 270 | d4t/3tc-containing | 1 |
| 271 | zdv/3tc-containing | 3 |
| 272 | fludarabine-containing | 2 |
| 273 | lamivudine-containing | 3 |
| 274 | pi-containing | 27 |
| 275 | nvp-containing | 5 |
| 276 | atv/r-containing | 1 |
| 277 | abacavir-containing | 6 |
| 278 | adefovir-containing | 3 |
| 279 | tenofovir-containing | 4 |
| 280 | efv-containing | 3 |
| 281 | pi-sparing | 3 |
| 282 | tnrti-sparing | 1 |
| 283 | individualising | 9 |
| 284 | phlebosclerosing | 1 |
| 285 | depilating | 1 |
| 286 | iodinating | 1 |
| 287 | gas-generating | 1 |
| 288 | molecular-targeting | 3 |
| 289 | lymphodepleting | 5 |
| 290 | tubulin-inhibiting | 2 |
| 291 | premelting | 2 |
| 292 | hypoxia-modifying | 3 |
| 293 | vacuum-drying | 1 |
| 294 | psl-antagonizing | 1 |
| 295 | tetra-drug | 1 |
| 296 | placebo/no-drug | 1 |
| 297 | ternary-drug | 2 |
| 298 | non-mph | 2 |
| 299 | non-mental-health | 1 |
| 300 | 0-12-month | 1 |
| 301 | e-zes+3-month | 5 |
| 302 | cbl-ipi | 1 |
| 303 | dual-nrti | 4 |
| 304 | mudpack | 5 |
| 305 | acute-attack | 2 |
| 306 | ≥12-week | 1 |
| 307 | f-week | 1 |
| 308 | 20‑week | 1 |
| 309 | c-met/alk | 1 |
| 310 | phamacological | 2 |
| 311 | erythromycin.pharmacological | 1 |
| 312 | non-parasitological | 1 |
| 313 | periodontological | 1 |
| 314 | perisurgical | 1 |
| 315 | roentrgenosurgical | 1 |
| 316 | hitorical | 1 |
| 317 | emprical | 1 |
| 318 | haptotherapeutical | 1 |
| 319 | pre-local | 1 |
| 320 | anti-haemorrhoidal | 1 |
| 321 | plurimodal | 1 |
| 322 | mta-multimodal | 1 |
| 323 | medicial | 1 |
| 324 | fasting/preprandial | 2 |
| 325 | antitrichomonial | 2 |
| 326 | veno-arterial | 12 |
| 327 | veno-veno-arterial | 2 |
| 328 | revascularizational | 1 |
| 329 | benefit/additional | 1 |
| 330 | intrventional | 1 |
| 331 | pseudooctahedral | 1 |
| 332 | anti-humoral | 1 |
| 333 | pre-referral | 8 |
| 334 | endo-aural | 1 |
| 335 | coequal | 2 |
| 336 | disease-free-interval | 1 |
| 337 | subgroup-level | 1 |
| 338 | post-docetaxel | 11 |
| 339 | lvr-coil | 3 |
| 340 | +nl | 2 |
| 341 | specol | 1 |
| 342 | nurse-proctocol | 1 |
| 343 | nitrazepam-ethanol | 1 |
| 344 | non-formoterol | 1 |
| 345 | streptokinase/control | 1 |
| 346 | cisplatin-taxol | 1 |
| 347 | 47-j/cm | 2 |
| 348 | standard-term | 2 |
| 349 | fluorouracil-platinum | 1 |
| 350 | nonplatinum | 15 |
| 351 | 2-regimen | 1 |
| 352 | device-driven | 2 |
| 353 | pitavastain | 1 |
| 354 | fluvastatin-niacin | 4 |
| 355 | omeprazole-amoxicillin | 2 |
| 356 | drug/insulin | 1 |
| 357 | pegylated-interferon-ribavirin | 1 |
| 358 | peg-interferon-α2/ribavirin | 2 |
| 359 | pre-statin | 2 |
| 360 | niaspan-statin | 1 |
| 361 | calgon | 1 |
| 362 | post-remission | 62 |
| 363 | postremission | 52 |
| 364 | consolidation/reintensification | 1 |
| 365 | three-combination | 4 |
| 366 | oocyte-donation | 3 |
| 367 | switch-induction | 2 |
| 368 | first-intention | 6 |
| 369 | prescription/nonprescription | 1 |
| 370 | eaaci/ga²len/edf/wao | 1 |
| 371 | chc/placebo | 1 |
| 372 | riociguat/placebo | 1 |
| 373 | treatment/no | 3 |
| 374 | iakentro | 1 |
| 375 | second-step | 28 |
| 376 | third-step | 3 |
| 377 | first-step | 67 |
| 378 | 1-methyl-4-phenylpyridinium/mptp | 1 |
| 379 | one‑year | 1 |
| 380 | intracanalicular | 2 |
| 381 | acdr | 18 |
| 382 | single-controller | 3 |
| 383 | su-per | 6 |
| 384 | water/wastewater | 4 |
| 385 | two-professional-rescuer | 1 |
| 386 | laver | 4 |
| 387 | pre-egfr | 2 |
| 388 | anthracycline-and/or | 2 |
| 389 | for/or | 1 |
| 390 | germanyfor | 1 |
| 391 | 24th-hour | 1 |
| 392 | marrow-versus-steroids | 1 |
| 393 | negotiates | 1 |
| 394 | antiuberculosis | 1 |
| 395 | hdl-atherosclerosis | 3 |
| 396 | heamodialysis | 1 |
| 397 | srp+prodentis | 1 |
| 398 | pi+2nrtis | 1 |
| 399 | aix-les-bains | 1 |
| 400 | non-hps | 1 |
| 401 | 2-class | 2 |
| 402 | tutor-less | 2 |
| 403 | behavioral-weight-loss | 1 |
| 404 | real-patients | 1 |
| 405 | never/previous | 1 |
| 406 | noncontinuous | 2 |
| 407 | rhgh=t | 1 |
| 408 | moist-heat | 8 |
| 409 | awt/epat | 1 |
| 410 | pas-c-diet | 1 |
| 411 | anitiplatelet | 1 |
| 412 | drawback/shift | 1 |
| 413 | observation-unit | 1 |
| 414 | neoadjvuant | 2 |
| 415 | cost-relevant | 1 |
| 416 | anticonvulsivant | 5 |
| 417 | pre-operative/neo-adjuvant | 2 |
| 418 | induction/adjuvant | 1 |
| 419 | coadjuvant | 10 |
| 420 | heme-independent | 2 |
| 421 | out‑patient | 1 |
| 422 | opioid-replacement | 1 |
| 423 | europe.treatment | 1 |
| 424 | `current | 1 |
| 425 | moxibustion-acupoint | 1 |
| 426 | anti-clot | 1 |
| 427 | last-resort | 13 |
| 428 | never/past | 2 |
| 429 | nonagonist | 1 |
| 430 | tnf-alpha-antagonist | 2 |
| 431 | antigout | 1 |
| 432 | asthma.new | 1 |
| 433 | pre-gtx | 1 |
| 434 | 200-mg/day | 1 |
| 435 | 400-mg/day | 1 |
| 436 | 4‑day | 1 |
| 437 | contemporay | 1 |
| 438 | 1-kgy | 1 |
| 439 | lipid-friendly | 1 |
| 440 | treatment+only | 1 |
| 441 | grazing-only | 1 |
| 442 | acetaminophen-only | 1 |
| 443 | compression-only | 24 |
| 444 | hands-only | 5 |
| 445 | strips-only | 1 |
| 446 | tangent-only | 1 |
| 447 | cast-only | 1 |
| 448 | psychotherapy-only | 1 |
| 449 | review.early | 1 |
| 450 | group.any | 1 |
| 451 | cidr/dietary | 1 |
| 452 | conventional-intensity | 1 |